Literature DB >> 27452039

Mechanisms of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis.

Shu Dong1, Qi-Long Chen, Ya-Nan Song, Yang Sun, Bin Wei, Xiao-Yan Li, Yi-Yang Hu, Ping Liu, Shi-Bing Su.   

Abstract

The classic toxicity of carbon tetrachloride (CCl4) is to induce liver lesion and liver fibrosis. Liver fibrosis is a consequence of chronic liver lesion, which can progress into liver cirrhosis even hepatocarcinoma. However, the toxicological mechanisms of CCl4-induced liver fibrosis remain not fully understood. We combined transcriptomic and proteomic analysis and biological network technology, predicted toxicological targets and regulatory networks of CCl4 in liver fibrosis. Wistar rats were treated with CCl4 for 9 weeks. Histopathological changes, hydroxyproline (Hyp) contents, serum ALT and AST in the CCl4-treated group were significantly higher than that of CCl4-untreated group. CCl4-treated and -untreated liver tissues were examined by microarray and iTRAQ. The results showed that 3535 genes (fold change ≥ 1.5, P < 0.05) and 1412 proteins (fold change ≥ 1.2, P < 0.05) were differentially expressed. Moreover, the integrative analysis of transcriptomics and proteomics data showed 523 overlapped proteins, enriched in 182 GO terms including oxidation reduction, response to oxidative stress, inflammatory response, extracellular matrix organization, etc. Furthermore, KEGG pathway analysis showed that 36 pathways including retinol metabolism, PPAR signaling pathway, glycolysis/gluconeogenesis, arachidonic acid metabolism, metabolism of xenobiotics by cytochrome P450 and drug metabolism. Network of protein-protein interaction (PPI) and key function with their related targets were performed and the degree of network was calculated with Cytoscape. The expression of key targets such as CYP4A3, ALDH2 and ALDH7A1 decreased after CCl4 treatment. Therefore, the toxicological mechanisms of CCl4-induced liver fibrosis may be related with multi biological process, pathway and targets which may provide potential protection reaction mechanism for CCl4 detoxication in the liver.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27452039     DOI: 10.2131/jts.41.561

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  36 in total

1.  Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.

Authors:  Sujita Sukumaran; Norihiro Watanabe; Pradip Bajgain; Kanchana Raja; Somala Mohammed; William E Fisher; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Cancer Discov       Date:  2018-06-07       Impact factor: 39.397

2.  Chinese herbal formula Fuzheng Huayu alleviates CCl4-induced liver fibrosis in rats: a transcriptomic and proteomic analysis.

Authors:  Shu Dong; Fei-Fei Cai; Qi-Long Chen; Ya-Nan Song; Yang Sun; Bin Wei; Xiao-Yan Li; Yi-Yang Hu; Ping Liu; Shi-Bing Su
Journal:  Acta Pharmacol Sin       Date:  2017-11-02       Impact factor: 6.150

Review 3.  Long Noncoding RNAs and Human Liver Disease.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Annu Rev Pathol       Date:  2021-08-20       Impact factor: 32.350

4.  Anti-liver fibrosis effects of the total flavonoids of litchi semen on CCl4-induced liver fibrosis in rats associated with the upregulation of retinol metabolism.

Authors:  Jiongyi Yan; Yinyi Feng; Xuewan Fang; Xiaojuan Cui; Xing Xia; Fang Li; Weisheng Luo; Jianqin Liang; Jianfang Feng; Kai Yu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

5.  Ameliorative Effect of Marine Macroalgae on Carbon Tetrachloride-Induced Hepatic Fibrosis and Associated Complications in Rats

Authors:  Maria Azam; Khan Hira; Shamim A Qureshi; Nasira Khatoon; Jehan Ara; Syed Ehteshamul-Haque
Journal:  Turk J Pharm Sci       Date:  2022-04-29

6.  Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways.

Authors:  Liwei Wu; Qinghui Zhang; Wenhui Mo; Jiao Feng; Sainan Li; Jingjing Li; Tong Liu; Shizan Xu; Wenwen Wang; Xiya Lu; Qiang Yu; Kan Chen; Yujing Xia; Jie Lu; Ling Xu; Yingqun Zhou; Xiaoming Fan; Chuanyong Guo
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

Review 7.  Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions.

Authors:  Sarah Y Neshat; Victor M Quiroz; Yuanjia Wang; Sebastian Tamayo; Joshua C Doloff
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 6.208

8.  Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice.

Authors:  Tulasi Yadati; Tom Houben; Albert Bitorina; Yvonne Oligschlaeger; Marion J Gijbels; Ronny Mohren; Dieter Lütjohann; Princy Khurana; Sandeep Goyal; Aditya Kulkarni; Jan Theys; Berta Cillero-Pastor; Ronit Shiri-Sverdlov
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

9.  CCM111 prevents hepatic fibrosis via cooperative inhibition of TGF-β, Wnt and STAT3 signaling pathways.

Authors:  In-Yu Lin; Yi-Shiou Chiou; Li-Ching Wu; Chen-Yu Tsai; Chiung-Tong Chen; Wu-Chang Chuang; Ming-Chung Lee; Ching-Che Lin; Ting-Ting Lin; Ssu-Ching Chen; Min-Hsiung Pan; Nianhan Ma
Journal:  J Food Drug Anal       Date:  2018-10-25       Impact factor: 6.157

10.  Identification of key metabolic changes during liver fibrosis progression in rats using a urine and serum metabolomics approach.

Authors:  Hong Chang; Hong-Yu Meng; Shu-Min Liu; Yu Wang; Xiao-Xu Yang; Fang Lu; Hong-Yu Wang
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.